Astrocytes: New targets for the treatment of neurodegenerative diseases

Current Pharmaceutical Design

Volumn 21, Issue 25, 2015, Pages 3570-3581

  Finsterwald, Charles ^a   Magistretti, Pierre J ^a,b,c   Lengacher, Sylvain ^a,c  

^a EPFL   (Switzerland)

^b KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Saudi Arabia)

^c Center for Psychiatric Neuroscience   (Switzerland)

Author keywords

Alzheimer disease; Amyotrophic lateral sclerosis; Astrocyte; Glia; Lactate; Metabolism; Neurodegeneration; Parkinson's disease

Indexed keywords

1,4 BENZODIOXAN 6 CARBOXYLIC ACID PIPERIDIDE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; AC 1202; ALPHA TOCOPHEROL; CEFTRIAXONE; CURCUMIN; CYANOCOBALAMIN; DICHLOROACETIC ACID; FOLIC ACID; GAMMA GLUTAMYLCYSTEINE ETHYL ESTER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMIC ACID; GLUTATHIONE; GLUTATHIONE ETHYL ESTER; GLYCOGEN; IDEBENONE; INSULIN; LEVACECARNINE; MESENCEPHALIC ASTROCYTE DERIVED NEUROTROPHIC FACTOR; METHANIAZIDE; OMEGA 3 FATTY ACID; PARDOPRUNOX; POLYPHENOL; PRAMIPEXOLE; PYRIDOXINE; S ADENOSYLMETHIONINE; SARIZOTAN; UBIQUINONE; VALPROIC ACID; ZONISAMIDE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ASTROCYTE; BRAIN CELL; BRAIN FUNCTION; BRAIN METABOLISM; BRAIN PROTECTION; CELL METABOLISM; COGNITION; DEGENERATIVE DISEASE; ELECTROENCEPHALOGRAM; ENERGY METABOLISM; HOMEOSTASIS; HUMAN; KETOGENIC DIET; LOW CARBOHYDRATE DIET; NERVE CELL DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SYNAPSE; TARGET CELL; ANIMAL; BRAIN CORTEX; DRUG DEVELOPMENT; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; NERVE CELL; NEURODEGENERATIVE DISEASES; PROCEDURES;

ANIMALS; ASTROCYTES; CEREBRAL CORTEX; DRUG DISCOVERY; ENERGY METABOLISM; HUMANS; MOLECULAR TARGETED THERAPY; NEURODEGENERATIVE DISEASES; NEURONS;

EID: 84940945157     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150710144502     Document Type: Article

References (170)

1. Attwell D, Laughlin SB. An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab 2001; 21: 1133-45.
2. Rasmussen P, Wyss MT, Lundby C. Cerebral glucose and lactate consumption during cerebral activation by physical activity in humans. FASEB J 2011; 25: 2865-73.
3. Chowdhury GM, Jiang L, Rothman DL, et al. The contribution of ketone bodies to basal and activity-dependent neuronal oxidation in vivo. J Cereb Blood Flow Metab 2014; 34: 1233-42.
4. Belanger M, Allaman I, Magistretti PJ. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab 2011; 14: 724-38.
5. Pellerin L, Magistretti PJ. Sweet sixteen for ANLS. J Cereb Blood Flow Metab 2012; 32: 1152-66.
6. Azevedo FA, Carvalho LR, Grinberg LT, et al. Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. J Comp Neurol 2009; 513: 532-41.
7. Herculano-Houzel S. The human brain in numbers: a linearly scaled-up primate brain. Front Hum Neurosci 2009; 3: 31.
8. Carmody RN, Wrangham RW. The energetic significance of cooking. J Hum Evol 2009; 57: 379-91.
9. Ogawa S, Lee TM, Kay AR, et al. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci USA 1990; 87: 9868-72.
10. Sokoloff L. Localization of functional activity in the central nervous system by measurement of glucose utilization with radioactive deoxyglucose. J Cereb Blood Flow Metab 1981; 1: 7-36.
11. Lajtha A. Handbook of Neurochemistry and molecular neurobiology. In: Gibson GE, G.A. D, Eds. 3rd ed. Springer 2007; p. 366.
12. Lowe MT, Faull RL, Christie DL, et al. Distribution of the creatine transporter throughout the human brain reveals a spectrum of creatine transporter immunoreactivity. J Comp Neurol 2015; 523: 699-725.
13. Dringen R. Metabolism and functions of glutathione in brain. Prog Neurobiol 2000; 62: 649-71.
14. Tiwari V, Ambadipudi S, Patel AB. Glutamatergic and GABAergic TCA cycle and neurotransmitter cycling fluxes in different regions of mouse brain. J Cereb Blood Flow Metab 2013; 33: 1523-31.
15. Magistretti PJ, Pellerin L. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos Trans R Soc Lond B Biol Sci 1999; 354: 1155-63.
16. Magistretti PJ, Morrison JH, Shoemaker WJ, et al. Vasoactive intestinal polypeptide induces glycogenolysis in mouse cortical slices: a possible regulatory mechanism for the local control of energy metabolism. Proc Natl Acad Sci USA 1981; 78: 6535-9.
17. Magistretti PJ, Morrison JH. Noradrenaline- and vasoactive intestinal peptide-containing neuronal systems in neocortex: functional convergence with contrasting morphology. Neuroscience 1988; 24: 367-78.
18. Bernardinelli Y, Magistretti PJ, Chatton JY. Astrocytes generate Na+-mediated metabolic waves. Proc Natl Acad Sci USA 2004; 101: 14937-42.
19. Attwell D, Buchan AM, Charpak S, et al. Glial and neuronal control of brain blood flow. Nature 2010; 468: 232-43.
20. Filosa JA, Iddings JA. Astrocyte regulation of cerebral vascular tone. Am J Physiol Heart Circ Physiol 2013; 305: H609-19.
21. Kleinfeld D, Blinder P, Drew PJ, et al. A guide to delineate the logic of neurovascular signaling in the brain. Front Neuroenergetics 2011; 3: 1.
22. Azarias G, Perreten H, Lengacher S, et al. Glutamate transport decreases mitochondrial pH and modulates oxidative metabolism in astrocytes. J Neurosci 2011; 31: 3550-9.
23. Jolivet R, Coggan JS, Allaman I, et al. Multi-timescale modeling of activity-dependent metabolic coupling in the neuron-gliavasculature ensemble. PLoS Comput Biol 2015; 11: e1004036.
24. Cerdan S, Rodrigues TB, Sierra A, et al. The redox switch/redox coupling hypothesis. Neurochem Int 2006; 48: 523-30.
25. Allaman I, Belanger M, Magistretti PJ. Methylglyoxal, the dark side of glycolysis. Front Neurosci 2015; 9: 23.
26. Deleidi M, Maetzler W. Protein clearance mechanisms of alphasynuclein and amyloid-Beta in lewy body disorders. Int J Alzheimers Dis 2012; 2012: 391438.
27. Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. Science 2013; 342: 373-7.
28. Schurr A, Payne RS, Miller JJ, et al. Glia are the main source of lactate utilized by neurons for recovery of function posthypoxia. Brain Res 1997; 774: 221-4.
29. Bliss TM, Ip M, Cheng E, et al. Dual-gene, dual-cell type therapy against an excitotoxic insult by bolstering neuroenergetics. J Neurosci 2004; 24: 6202-8.
30. Berthet C, Lei H, Thevenet J, et al. Neuroprotective role of lactate after cerebral ischemia. J Cereb Blood Flow Metab 2009; 29: 1780- 9.
31. Suzuki A, Stern SA, Bozdagi O, et al. Astrocyte-neuron lactate transport is required for long-term memory formation. Cell 2011; 144: 810-23.
32. Newman LA, Korol DL, Gold PE. Lactate produced by glycogenolysis in astrocytes regulates memory processing. PLoS One 2011; 6: e28427.
33. Yang J, Ruchti E, Petit JM, et al. Lactate promotes plasticity gene expression by potentiating NMDA signaling in neurons. Proc Natl Acad Sci USA 2014; 111: 12228-33.
34. Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012; 148: 1204-22.
35. Thomas SC, Alhasawi A, Appanna VP, et al. Brain metabolism and Alzheimer's disease: the prospect of a metabolite-based therapy. J Nutr Health Aging 2015; 19: 58-63.
36. Tanzi RE. The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2.
37. Teich AF, Arancio O. Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant? Biochem J 2012; 446: 165-77.
38. Parihar MS, Brewer GJ. Amyloid-beta as a modulator of synaptic plasticity. J Alzheimers Dis 2010; 22: 741-63.
39. Spuch C, Ortolano S, Navarro C. New insights in the amyloid-Beta interaction with mitochondria. J Aging Res 2012; 2012: 324968.
40. Pimplikar SW. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int J Biochem Cell Biol 2009; 41: 1261-8.
41. Giannakopoulos P, Kovari E, Gold G, et al. Pathological substrates of cognitive decline in Alzheimer's disease. Front Neurol Neurosci 2009; 24: 20-29.
42. Fu W, Jhamandas JH. Role of astrocytic glycolytic metabolism in Alzheimer's disease pathogenesis. Biogerontology 2014; 15: 579- 86.
43. Demetrius LA, Driver J. Alzheimer's as a metabolic disease. Biogerontology 2013; 14: 641-9.
44. Demetrius LA, Magistretti PJ, Pellerin L. Alzheimer's disease: the amyloid hypothesis and the Inverse Warburg effect. Front Physiol 2014; 5: 522.
45. Tomi M, Zhao Y, Thamotharan S, et al. Early life nutrient restriction impairs blood-brain metabolic profile and neurobehavior predisposing to Alzheimer's disease with aging. Brain Res 2013; 1495: 61-75.
46. Ferreira IL, Resende R, Ferreiro E, et al. Multiple defects in energy metabolism in Alzheimer's disease. Curr Drug Targets 2010; 11: 1193-206.
47. Beal MF. Oxidative damage as an early marker of Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 2005; 26: 585-6.
48. Yao J, Brinton RD. Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment. Curr Pharm Des 2011; 17: 3474-9.
49. Brooks WM, Lynch PJ, Ingle CC, et al. Gene expression profiles of metabolic enzyme transcripts in Alzheimer's disease. Brain Res 2007; 1127: 127-35.
50. Kaddurah-Daouk R, Zhu H, Sharma S, et al. Alterations in metabolic pathways and networks in Alzheimer's disease. Transl Psychiatry 2013; 3: e244.
51. Erickson MA, Banks WA. Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. J Cereb Blood Flow Metab 2013; 33: 1500-13.
52. Woo BK, Harwood DG, Melrose RJ, et al. Executive deficits and regional brain metabolism in Alzheimer's disease. Int J Geriatr Psychiatry 2010; 25: 1150-8.
53. Esposito L, Raber J, Kekonius L, et al. Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice. J Neurosci 2006; 26: 5167- 79.
54. Nagele RG, D'Andrea MR, Lee H, et al. Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res 2003; 971: 197-209.
55. Kurt MA, Davies DC, Kidd M. beta-Amyloid immunoreactivity in astrocytes in Alzheimer's disease brain biopsies: an electron microscope study. Exp Neurol 1999; 158: 221-8.
56. Koistinaho M, Lin S, Wu X, et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 2004; 10: 719-26.
57. Nagele RG, Wegiel J, Venkataraman V, et al. Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol Aging 2004; 25: 663-74.
58. Forman MS, Lal D, Zhang B, et al. Transgenic mouse model of tau pathology in astrocytes leading to nervous system degeneration. J Neurosci 2005; 25: 3539-50.
59. Kim K, Lee SG, Kegelman TP, et al. Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J Cell Physiol 2011; 226: 2484-93.
60. Tian G, Kong Q, Lai L, et al. Increased expression of cholesterol 24S-hydroxylase results in disruption of glial glutamate transporter EAAT2 association with lipid rafts: a potential role in Alzheimer's disease. J Neurochem 2010; 113: 978-89.
61. Kulijewicz-Nawrot M, Sykova E, Chvatal A, et al. Astrocytes and glutamate homoeostasis in Alzheimer's disease: a decrease in glutamine synthetase, but not in glutamate transporter-1, in the prefrontal cortex. ASN Neuro 2013; 5: 273-82.
62. Simpson JE, Ince PG, Lace G, et al. Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol Aging 2010; 31: 578-90.
63. Allaman I, Gavillet M, Belanger M, et al. Amyloid-beta aggregates cause alterations of astrocytic metabolic phenotype: impact on neuronal viability. J Neurosci 2010; 30: 3326-38.
64. Lim D, Ronco V, Grolla AA, et al. Glial calcium signalling in Alzheimer's disease. Rev Physiol Biochem Pharmacol 2014; 167: 45-65.
65. Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci 2008; 31: 454-63.
66. Ticozzi N, Tiloca C, Morelli C, et al. Genetics of familial Amyotrophic lateral sclerosis. Arch Ital Biol 2011; 149: 65-82.
67. Chen S, Sayana P, Zhang X, et al. Genetics of amyotrophic lateral sclerosis: an update. Mol Neurodegener 2013; 8: 28.
68. Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006; 52: 39-59.
69. Haidet-Phillips AM, Hester ME, Miranda CJ, et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol 2011; 29: 824-8.
70. Re DB, Le Verche V, Yu C, et al. Necroptosis drives motor neuron death in models of both sporadic and familial ALS. Neuron 2014; 81: 1001-8.
71. Wong PC, Pardo CA, Borchelt DR, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995; 14: 1105-16.
72. Bruijn LI, Houseweart MK, Kato S, et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998; 281: 1851-4.
73. Vijayvergiya C, Beal MF, Buck J, et al. Mutant superoxide dismutase 1 forms aggregates in the brain mitochondrial matrix of amyotrophic lateral sclerosis mice. J Neurosci 2005; 25: 2463-70.
74. Saccon RA, Bunton-Stasyshyn RK, Fisher EM, et al. Is SOD1 loss of function involved in amyotrophic lateral sclerosis? Brain 2013; 136: 2342-58.
75. Rothstein JD, Tsai G, Kuncl RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990; 28: 18-25.
76. Spreux-Varoquaux O, Bensimon G, Lacomblez L, et al. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci 2002; 193: 73-78.
77. Philips T, Rothstein JD. Glial cells in amyotrophic lateral sclerosis. Exp Neurol 2014; 262 Pt B: 111-20.
78. Sasaki S, Komori T, Iwata M. Excitatory amino acid transporter 1 and 2 immunoreactivity in the spinal cord in amyotrophic lateral sclerosis. Acta Neuropathol 2000; 100: 138-44.
79. Bruijn LI, Becher MW, Lee MK, et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997; 18: 327-38.
80. Howland DS, Liu J, She Y, et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci USA 2002; 99: 1604-9.
81. Tanaka K, Watase K, Manabe T, et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 1997; 276: 1699-702.
82. Boston-Howes W, Gibb SL, Williams EO, et al. Caspase-3 cleaves and inactivates the glutamate transporter EAAT2. J Biol Chem 2006; 281: 14076-84.
83. Trotti D, Rolfs A, Danbolt NC, et al. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat Neurosci 1999; 2: 427-33.
84. Lee Y, Morrison BM, Li Y, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 2012; 487: 443-8.
85. Davie CA. A review of Parkinson's disease. Br Med Bull 2008; 86: 109-27.
86. Hardy J, Lewis P, Revesz T, et al. The genetics of Parkinson's syndromes: a critical review. Curr Opin Genet Dev 2009; 19: 254- 65.
87. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33-39.
88. Malkus KA, Tsika E, Ischiropoulos H. Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle. Mol Neurodegener 2009; 4: 24.
89. Ciesielska A, Joniec I, Kurkowska-Jastrzebska I, et al. The impact of age and gender on the striatal astrocytes activation in murine model of Parkinson's disease. Inflamm Res 2009; 58: 747-53.
90. Muramatsu Y, Kurosaki R, Watanabe H, et al. Cerebral alterations in a MPTP-mouse model of Parkinson's disease--an immunocytochemical study. J Neural Transm 2003; 110: 1129-44.
91. Lee HJ, Suk JE, Patrick C, et al. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 2010; 285: 9262-72.
92. Vila M, Ramonet D, Perier C. Mitochondrial alterations in Parkinson's disease: new clues. J Neurochem 2008; 107: 317-28.
93. Devi L, Raghavendran V, Prabhu BM, et al. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 2008; 283: 9089-100.
94. Rappold PM, Tieu K. Astrocytes and therapeutics for Parkinson's disease. Neurotherapeutics 2010; 7: 413-23.
95. Damier P, Hirsch EC, Zhang P, et al. Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 1993; 52: 1-6.
96. Zeevalk GD, Razmpour R, Bernard LP. Glutathione and Parkinson's disease: is this the elephant in the room? Biomed Pharmacother 2008; 62: 236-49.
97. Niranjan R. The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson's disease: focus on astrocytes. Mol Neurobiol 2014; 49: 28-38.
98. Yasuda T, Mochizuki H. Use of growth factors for the treatment of Parkinson's disease. Expert Rev Neurother 2010; 10: 915-24.
99. Proschel C, Stripay JL, Shih CH, et al. Delayed transplantation of precursor cell-derived astrocytes provides multiple benefits in a rat model of Parkinsons. EMBO Mol Med 2014; 6: 504-18.
100. Hansen RA, Gartlehner G, Webb AP, et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging 2008; 3: 211-25.
101. Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer's disease. Ther Adv Neurol Disord 2013; 6: 19-33.
102. Schneider LS, Mangialasche F, Andreasen N, et al. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med 2014; 275: 251-83.
103. Galimberti D, Scarpini E. Alzheimer's disease: from pathogenesis to disease-modifying approaches. CNS Neurol Disord Drug Targets 2011; 10: 163-74.
104. Martinez A, Perez DI. GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease? J Alzheimers Dis 2008; 15: 181- 91.
105. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 2009; 110: 1129-34.
106. Barten DM, Albright CF. Therapeutic strategies for Alzheimer's disease. Mol Neurobiol 2008; 37: 171-86.
107. Mecocci P, Polidori MC. Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. Biochim Biophys Acta 2012; 1822: 631-8.
108. Gutzmann H, Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year doubleblind multicentre study. J Neural Transm Suppl 1998; 54: 301-10.
109. Weyer G, Babej-Dolle RM, Hadler D, et al. A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. Neuropsychobiology 1997; 36: 73-82.
110. Galasko DR, Peskind E, Clark CM, et al. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 2012; 69: 836-41.
111. Park E, Yu KH, Kim do K, et al. Protective effects of Nacetylcysteine against monosodium glutamate-induced astrocytic cell death. Food Chem Toxicol 2014; 67: 1-9.
112. Fu AL, Dong ZH, Sun MJ. Protective effect of N-acetyl-L-cysteine on amyloid beta-peptide-induced learning and memory deficits in mice. Brain Res 2006; 1109: 201-6.
113. Huang Q, Aluise CD, Joshi G, et al. Potential in vivo amelioration by N-acetyl-L-cysteine of oxidative stress in brain in human double mutant APP/PS-1 knock-in mice: toward therapeutic modulation of mild cognitive impairment. J Neurosci Res 2010; 88: 2618-29.
114. Adair JC, Knoefel JE, Morgan N. Controlled trial of Nacetylcysteine for patients with probable Alzheimer's disease. Neurology 2001; 57: 1515-7.
115. Remington R, Chan A, Paskavitz J, et al. Efficacy of a vitamin/ nutriceutical formulation for moderate-stage to later-stage Alzheimer's disease: a placebo-controlled pilot study. Am J Alzheimers Dis Other Demen 2009; 24: 27-33.
116. Remington R, Bechtel C, Larsen D, et al. A Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in Alzheimer's Disease. J Alzheimers Dis 2015.
117. Balietti M, Casoli T, Di Stefano G, et al. Ketogenic diets: an historical antiepileptic therapy with promising potentialities for the aging brain. Ageing Res Rev 2010; 9: 273-9.
118. Gasior M, Rogawski MA, Hartman AL. Neuroprotective and disease- modifying effects of the ketogenic diet. Behav Pharmacol 2006; 17: 431-9.
119. Yao J, Chen S, Mao Z, et al. 2-Deoxy-D-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer's disease. PLoS One 2011; 6: e21788.
120. Van der Auwera I, Wera S, Van Leuven F, et al. A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease. Nutr Metab (Lond) 2005; 2: 28.
121. Kashiwaya Y, Bergman C, Lee JH, et al. A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease. Neurobiol Aging 2013; 34: 1530-9.
122. Krikorian R, Shidler MD, Dangelo K, et al. Dietary ketosis enhances memory in mild cognitive impairment. Neurobiol Aging 2012; 33: 425.e19-27.
123. Henderson ST, Vogel JL, Barr LJ, et al. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond) 2009; 6: 31.
124. Sullivan PG, Rippy NA, Dorenbos K, et al. The ketogenic diet increases mitochondrial uncoupling protein levels and activity. Ann Neurol 2004; 55: 576-80.
125. Jarrett SG, Milder JB, Liang LP, et al. The ketogenic diet increases mitochondrial glutathione levels. J Neurochem 2008; 106: 1044-51.
126. Bianchetti A, Rozzini R, Trabucchi M. Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors. Curr Med Res Opin 2003; 19: 350-3.
127. Pellerin L, Magistretti PJ. Ampakine CX546 bolsters energetic response of astrocytes: a novel target for cognitive-enhancing drugs acting as alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulators. J Neurochem 2005; 92: 668-77.
128. Bahr BA, Bendiske J, Brown QB, et al. Survival signaling and selective neuroprotection through glutamatergic transmission. Exp Neurol 2002; 174: 37-47.
129. Brix B, Mesters JR, Pellerin L, et al. Endothelial cell-derived nitric oxide enhances aerobic glycolysis in astrocytes via HIF-1alphamediated target gene activation. J Neurosci 2012; 32: 9727-35.
130. Rosafio K, Pellerin L. Oxygen tension controls the expression of the monocarboxylate transporter MCT4 in cultured mouse cortical astrocytes via a hypoxia-inducible factor-1alpha-mediated transcriptional regulation. Glia 2014; 62: 477-90.
131. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012; 69: 29-38.
132. Freiherr J, Hallschmid M, Frey WH 2nd, et al. Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 2013; 27: 505-14.
133. Bingham EM, Hopkins D, Smith D, et al. The role of insulin in human brain glucose metabolism: an 18fluoro-deoxyglucose positron emission tomography study. Diabetes 2002; 51: 3384-90.
134. Heni M, Hennige AM, Peter A, et al. Insulin promotes glycogen storage and cell proliferation in primary human astrocytes. PLoS One 2011; 6: e21594.
135. Colton CK, Kong Q, Lai L, et al. Identification of translational activators of glial glutamate transporter EAAT2 through cell-based high-throughput screening: an approach to prevent excitotoxicity. J Biomol Screen 2010; 15: 653-62.
136. Kong Q, Chang LC, Takahashi K, et al. Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection. J Clin Invest 2014; 124: 1255-67.
137. Rothstein JD, Patel S, Regan MR, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005; 433: 73-77.
138. Soni N, Reddy BV, Kumar P. GLT-1 transporter: an effective pharmacological target for various neurological disorders. Pharmacol Biochem Behav 2014; 127: 70-81.
139. Berry JD, Shefner JM, Conwit R, et al. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One 2013; 8: e61177.
140. Cassina P, Cassina A, Pehar M, et al. Mitochondrial dysfunction in SOD1G93A-bearing astrocytes promotes motor neuron degeneration: prevention by mitochondrial-targeted antioxidants. J Neurosci 2008; 28: 4115-22.
141. Miquel E, Cassina A, Martinez-Palma L, et al. Neuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis. Free Radic Biol Med 2014; 70: 204-13.
142. Miquel E, Cassina A, Martinez-Palma L, et al. Modulation of astrocytic mitochondrial function by dichloroacetate improves survival and motor performance in inherited amyotrophic lateral sclerosis. PLoS One 2012; 7: e34776.
143. Zhao Z, Lange DJ, Voustianiouk A, et al. A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC Neurosci 2006; 7: 29.
144. Paganoni S, Wills AM. High-fat and ketogenic diets in amyotrophic lateral sclerosis. J Child Neurol 2013; 28: 989-92.
145. Jiang H, Tian X, Guo Y, et al. Activation of nuclear factor erythroid 2-related factor 2 cytoprotective signaling by curcumin protect primary spinal cord astrocytes against oxidative toxicity. Biol Pharm Bull 2011; 34: 1194-7.
146. Dong H, Xu L, Wu L, et al. Curcumin abolishes mutant TDP-43 induced excitability in a motoneuron-like cellular model of ALS. Neuroscience 2014; 272: 141-53.
147. Sprenger F, Poewe W. Management of motor and non-motor symptoms in Parkinson's disease. CNS Drugs 2013; 27: 259-72.
148. Olanow CW, Schapira AH. Therapeutic prospects for Parkinson disease. Ann Neurol 2013; 74: 337-47.
149. Hauser RA, Lyons KE, McClain T, et al. Randomized, doubleblind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov Disord 2009; 24: 979-83.
150. Zeevalk GD, Manzino L, Sonsalla PK, et al. Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease. Exp Neurol 2007; 203: 512-20.
151. Chinta SJ, Rajagopalan S, Butterfield DA, et al. In vitro and in vivo neuroprotection by gamma-glutamylcysteine ethyl ester against MPTP: relevance to the role of glutathione in Parkinson's disease. Neurosci Lett 2006; 402: 137-41.
152. Allen GF, Ullah Y, Hargreaves IP, et al. Dopamine but not l-dopa stimulates neural glutathione metabolism. Potential implications for Parkinson's and other dopamine deficiency states. Neurochem Int 2013; 62: 684-94.
153. Asanuma M, Miyazaki I, Diaz-Corrales FJ, et al. Neuroprotective effects of zonisamide target astrocyte. Ann Neurol 2010; 67: 239- 49.
154. Arawaka S, Fukushima S, Sato H, et al. Zonisamide attenuates alpha-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease. PLoS One 2014; 9: e89076.
155. Grover ND, Limaye RP, Gokhale DV, et al. Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease. Indian J Pharmacol 2013; 45: 547-55.
156. Miyazaki I, Asanuma M, Murakami S, et al. Targeting 5-HT(1A) receptors in astrocytes to protect dopaminergic neurons in Parkinsonian models. Neurobiol Dis 2013; 59: 244-56.
157. Dupre KB, Eskow KL, Barnum CJ, et al. Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology 2008; 55: 1321-8.
158. Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebocontrolled trial. Mov Disord 2007; 22: 179-86.
159. Sampaio C, Bronzova J, Hauser RA, et al. Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials. Mov Disord 2011; 26: 1464-76.
160. Vanitallie TB, Nonas C, Di Rocco A, et al. Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. Neurology 2005; 64: 728-30.
161. Tieu K, Perier C, Caspersen C, et al. D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest 2003; 112: 892-901.
162. Voutilainen MH, Back S, Porsti E, et al. Mesencephalic astrocytederived neurotrophic factor is neurorestorative in rat model of Parkinson's disease. J Neurosci 2009; 29: 9651-9.
163. Cunningham LA, Su C. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease. Exp Neurol 2002; 174: 230-42.
164. Nutt JG, Burchiel KJ, Comella CL, et al. Randomized, doubleblind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003; 60: 69-73.
165. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006; 59: 459-66.
166. Chen PS, Peng GS, Li G, et al. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 2006; 11: 1116-25.
167. Sriram A, Ward HE, Hassan A, et al. Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease. J Neurol 2013; 260: 521-7.
168. Hicks CW, Pandya MM, Itin I, et al. Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease. Parkinsonism Relat Disord 2011; 17: 379-81.
169. Li C, Zhao R, Gao K, et al. Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2011; 8: 67-80.
170. Amor S, Puentes F, Baker D, et al. Inflammation in neurodegenerative diseases. Immunology 2010; 129: 154-69.